Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Vamicamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 known ✓ | Q12809 | 4/20 | 0.64 |
| ▸ | OPRK1 known ✓ | P41145 | 2/20 | 0.64 |
| ▸ | ADRB3 known ✓ | P13945 | 1/20 | 0.64 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.64 |
| ▸ | GRIN1 known ✓ | Q05586 | 6/20 | 0.59 |
| ▸ | GRIN2A known ✓ | Q12879 | 6/20 | 0.59 |
| ▸ | GRIN2D known ✓ | O15399 | 5/20 | 0.59 |
| ▸ | GRIN2C known ✓ | Q14957 | 5/20 | 0.59 |
| ▸ | GRIN2B known ✓ | Q13224 | 4/20 | 0.59 |
| ▸ | OPRM1 known ✓ | P35372 | 3/20 | 0.59 |
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 0.59 |
| ▸ | CACNA1F known ✓ | O60840 | 1/20 | 0.59 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.59 |
| ▸ | OPRD1 known ✓ | P41143 | 1/20 | 0.59 |
| ▸ | CACNA1D known ✓ | Q01668 | 1/20 | 0.59 |
| ▸ | CACNA1S known ✓ | Q13698 | 1/20 | 0.59 |
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 0.59 |
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.42 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.42 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vamicamide SCHEMBL9393357 | 1.00 | KCNH2 (0.64) | KCNH2OPRK1BLMSLC22A2SLC22A1 | |
| Vamicamide SCHEMBL30700593 | 0.99 | KCNH2 (0.65) | KCNH2OPRK1BLMSLC22A2SLC22A1 | |
| Vamicamide SCHEMBL9393264 | 0.99 | KCNH2 (0.65) | KCNH2OPRK1BLMSLC22A2SLC22A1 | |
| Vamicamide SCHEMBL331820 | 0.99 | KCNH2 (0.65) | KCNH2OPRK1BLMSLC22A2SLC22A1 | |
| Aminopentamide Sulfate SCHEMBL251458 | 0.84 | GRIN1 (0.75) | KCNH2OPRK1BLMSLC22A2SLC22A1 | |
| Disopyramide SCHEMBL546251 | 0.80 | KCNH2 (0.98) | KCNH2OPRK1BLMSLC22A2SLC22A1 | |
| Aminopentamide Sulfate SCHEMBL203612 | 0.79 | GRIN1 (0.68) | KCNH2OPRK1BLMSLC22A2SLC22A1 | |
| Disopyramide SCHEMBL23931452 | 0.78 | KCNH2 (1.00) | KCNH2OPRK1BLMSLC22A2SLC22A1 | |
| Disopyramide SCHEMBL16153 | 0.78 | KCNH2 (1.00) | KCNH2OPRK1BLMSLC22A2SLC22A1 | |
| (S)-Disopyramide SCHEMBL41811 | 0.78 | KCNH2 (1.00) | KCNH2OPRK1BLMSLC22A2SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1915992-A1 | USE OF CYCLOOXYGENASE INHIBITORS AND ANTIMUSCARINIC AGENTS FOR THE TREATMENT OF INCONTINENCE | Pharmacia Corporation (US) | 2008-04-30 | — | — | EP | claimed |
| WO-2007072503-A2 | COMBINATIONS FOR MANAGING INFLAMMATION AND ASSOCIATED DISORDERS | PANACEA BIOTEC LTD. (IN) | 2007-06-28 | — | — | WO | claimed |
| US-20050261328-A1 | Pharmaceutical composition comprising beta-3-adrenoceptor-agonists and antimuscarinic agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | US | claimed |
| CN-1633283-A | Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence | PHARMACIA CORP (US) | 2005-06-29 | — | — | CN | claimed |
| EP-1476146-A1 | USE OF CYCLOOXYGENASE INHIBITORS AND ANTIMUSCARINIC AGENTS FOR THE TREATMENT OF INCONTINENCE | Pharmacia Corporation (US) | 2004-11-17 | — | — | EP | claimed |
| US-20030191172-A1 | Method of using cyclooxygenase inhibitors and antimuscarinic agents | VERSI EBRAHIM (US) | 2003-10-09 | — | — | US | claimed |
| WO-2003070233-A1 | USE OF CYCLOOXYGENASE INHIBITORS AND ANTIMUSCARINIC AGENTS FOR THE TREATMENT OF INCONTINENCE | PHARMACIA CORPORATION (US) | 2003-08-28 | — | — | WO | claimed |
| EP-1915992-A1 | USE OF CYCLOOXYGENASE INHIBITORS AND ANTIMUSCARINIC AGENTS FOR THE TREATMENT OF INCONTINENCE | Pharmacia Corporation (US) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007072503-A2 | COMBINATIONS FOR MANAGING INFLAMMATION AND ASSOCIATED DISORDERS | PANACEA BIOTEC LTD. (IN) | 2007-06-28 | — | — | WO | disclosed |
| US-20070078181-A1 | Use of a beta-3-agonist for the treatment of patients with spinal cord injury and suffering from renal and bladder complaints | MICHEL MARTIN C | 2007-04-05 | — | — | US | disclosed |
| US-20060084700-A1 | Use of a beta-3 agonist for the treatment of disorders of the prostate and of the lower urogenital tract | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-04-20 | — | — | US | disclosed |
| US-20050261328-A1 | Pharmaceutical composition comprising beta-3-adrenoceptor-agonists and antimuscarinic agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | US | disclosed |
| CN-1633283-A | Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence | PHARMACIA CORP (US) | 2005-06-29 | — | — | CN | disclosed |
| EP-0452809-B1 | A therapeutic agent for pollakiuria, urinary urgency or incontinence of urine comprising alpha-phenyl-alpha-pyridylalkanoic acid derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-07-27 | — | — | EP | disclosed |
| EP-0452809-A2 | A therapeutic agent for pollakiuria, urinary urgency or incontinence of urine comprising alpha-phenyl-alpha-pyridylalkanoic acid derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261328-A1 | Pharmaceutical composition comprising beta-3-adrenoceptor-agonists and antimuscarinic agents | ADRB3, ADRB2, ADRB1 | KCNH2 816/4885OPRK1 44/4885ADRB3 1/4885 |
| US-20060084700-A1 | Use of a beta-3 agonist for the treatment of disorders of the prostate and of the lower urogenital tract | ADRB3, ADRB2, ADRB1 | KCNH2 2041/4885OPRK1 65/4885ADRB3 1/4885 |
| US-20070078181-A1 | Use of a beta-3-agonist for the treatment of patients with spinal cord injury and suffering from renal and bladder complaints | ADRB3, ADRB2, ADRB1 | KCNH2 466/4885OPRK1 16/4885ADRB3 1/4885 |
| US-20030191172-A1 | Method of using cyclooxygenase inhibitors and antimuscarinic agents | PTGS2, PTGES2, PTGS1 | KCNH2 2454/4885OPRK1 123/4885ADRB3 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.